What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Prostate cancer, Internal medicine, Oncology, Surgery and Cancer.
His research integrates issues of Prostate, Randomized controlled trial, Docetaxel and Hazard ratio in his study of Prostate cancer.
Michael A. Carducci has included themes like Gastroenterology and Endocrinology in his Internal medicine study.
His Oncology research is multidisciplinary, relying on both Cabazitaxel, Clinical trial, Circulating tumor cell, Enzalutamide and Gynecology.
Michael A. Carducci interconnects Placebo, Combination therapy, Peripheral edema and Urology in the investigation of issues within Surgery.
His studies in Cancer integrate themes in fields like Adverse effect, Pharmacokinetics and Quality of life.
His most cited work include:
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. (3028 citations)
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (1635 citations)
- AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. (1567 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Prostate cancer, Oncology, Cancer and Cancer research.
His Internal medicine study combines topics in areas such as Endocrinology and Surgery.
He has researched Prostate cancer in several fields, including Prostate, Docetaxel and Urology.
His Oncology research includes elements of Clinical endpoint, Enzalutamide, Proportional hazards model and Phases of clinical research.
His studies deal with areas such as Pharmacokinetics and Pharmacology as well as Cancer.
His Cancer research research incorporates elements of Histone deacetylase, Immunology and Pathology.
He most often published in these fields:
- Internal medicine (58.78%)
- Prostate cancer (54.39%)
- Oncology (48.75%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.78%)
- Prostate cancer (54.39%)
- Oncology (48.75%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Prostate cancer, Oncology, Cancer and Clinical trial.
Hazard ratio, Disease, Nivolumab, Phases of clinical research and Enzalutamide are among the areas of Internal medicine where Michael A. Carducci concentrates his study.
His Prostate cancer research integrates issues from Androgen, Randomized controlled trial, Docetaxel and Cancer research.
His biological study spans a wide range of topics, including Brief Pain Inventory and Urology.
His work in the fields of Oncology, such as Renal cell carcinoma, overlaps with other areas such as SABR volatility model.
Michael A. Carducci interconnects Health equity, Health literacy, Psychological intervention and Family medicine in the investigation of issues within Clinical trial.
Between 2017 and 2021, his most popular works were:
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (243 citations)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (204 citations)
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial (133 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Michael A. Carducci mainly investigates Internal medicine, Oncology, Prostate cancer, Nivolumab and Renal cell carcinoma.
His study in Adverse effect, Clinical trial, Disease, Pazopanib and Prostate are all subfields of Internal medicine.
His Oncology study combines topics in areas such as Cancer, Tolerability, Radiation therapy and Systemic therapy.
His Prostate cancer research is multidisciplinary, incorporating elements of Androgen, Randomized controlled trial, Docetaxel and Hazard ratio.
His Nivolumab research also works with subjects such as
- Ipilimumab and related Sunitinib,
- Kidney cancer which is related to area like Everolimus.
His Renal cell carcinoma study combines topics from a wide range of disciplines, such as Adjuvant and Immune system.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
